Using machine learning to identify patients with cancer that would benefit from immunotherapy
A new study examines the development of two machine learning models to classify the immunophenotype of a cancer specimen.
Apr 16, 2024
0
0
A new study examines the development of two machine learning models to classify the immunophenotype of a cancer specimen.
Apr 16, 2024
0
0
Cancer cells grow and spread by hiding from the body's immune system. Immunotherapy allows the immune system to find and attack hidden cancer cells, helping cancer patients live longer lives. However, many patients get little ...
Apr 16, 2024
0
63
In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances. But while immunotherapy drugs offer new treatment possibilities, only about 20% to 40% of patients respond ...
Apr 11, 2024
0
1
Researchers from the School of Biomedical Engineering & Imaging Sciences (BMEIS) have published a systematic review in Neuro-Oncology Advances exploring the use of MRI imaging techniques to identify non-invasive biomarkers ...
Apr 11, 2024
0
0
Researchers with McMaster University have crafted the first-ever guidelines to help prepare families who plan to build their child's tolerance to common food allergens.
Apr 8, 2024
0
0
A pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that for people with borderline resectable pancreatic cancer, administrating an immunotherapy drug in combination with chemotherapy ...
Apr 5, 2024
0
2
An initial phase of multifood sublingual immunotherapy (SLIT) that bypasses oral immunotherapy (OIT) buildup is safe and effective, according to a study published online Feb. 27 in the Journal of Allergy and Clinical Immunology: ...
Mar 24, 2024
0
18
Researchers have developed a genetic test that can identify how patients with triple negative early-stage breast cancer will respond to immunotherapy drugs. This means that patients who are unlikely to respond to these drugs ...
Mar 19, 2024
0
7
Tumor mutation burden (TMB) is considered an important predictive biomarker for the efficacy of immunotherapy. However, in cancer types where TMB is not positively correlated with the abundance of CD8+ T cells, TMB cannot ...
Mar 19, 2024
0
0
Jonathan Chen, MD, Ph.D., an investigator in the Department of Pathology at Massachusetts General Hospital, and Nir Hacohen, Ph.D., director of the Center of Cancer Immunology at Massachusetts General Hospital, are co-authors ...
Mar 19, 2024
0
0